Connor, Clark & Lunn Investment Management Ltd. Exelixis, Inc. Transaction History

Connor, Clark & Lunn Investment Management Ltd.

$18.8 Billion
Q3 2024

A detailed history of Connor, Clark & Lunn Investment Management Ltd. transactions in Exelixis, Inc. stock. As of the latest transaction made, Connor, Clark & Lunn Investment Management Ltd. holds 75,995 shares of EXEL stock, worth $2.63 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares

75,995

Holding current value

$2.63 Million

% of portfolio

0.01%

16 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 08, 2024	BUY	$21.96 - $27.6 $1.67 Million - $2.1 Million	75,995 New	75,995 $1.97 Million
Q3 2023 Nov 13, 2023	SELL	$19.04 - $22.74 $2.19 Million - $2.62 Million	-115,025 Reduced 37.63%	190,637 $4.17 Million
Q2 2023 Aug 10, 2023	SELL	$18.17 - $20.48 $3.28 Million - $3.69 Million	-180,269 Reduced 37.1%	305,662 $5.84 Million
Q1 2023 May 09, 2023	BUY	$16.3 - $19.41 $1.86 Million - $2.21 Million	113,899 Added 30.62%	485,931 $9.43 Million
Q4 2022 Feb 10, 2023	BUY	$14.96 - $17.39 $5.23 Million - $6.08 Million	349,910 Added 1581.73%	372,032 $5.97 Million
Q3 2022 Nov 10, 2022	SELL	$15.68 - $22.27 $3.09 Million - $4.39 Million	-197,284 Reduced 89.92%	22,122 $347,000
Q2 2022 Aug 05, 2022	SELL	$17.44 - $23.16 $1.74 Million - $2.31 Million	-99,638 Reduced 31.23%	219,406 $4.57 Million
Q1 2022 May 12, 2022	BUY	$17.03 - $22.67 $2.22 Million - $2.95 Million	130,333 Added 69.06%	319,044 $7.23 Million
Q4 2021 Feb 10, 2022	SELL	$15.84 - $21.88 $186,737 - $257,943	-11,789 Reduced 5.88%	188,711 $3.45 Million
Q3 2021 Nov 12, 2021	BUY	$16.3 - $21.14 $2.57 Million - $3.33 Million	157,587 Added 367.22%	200,500 $4.24 Million
Q2 2021 Aug 12, 2021	BUY	$17.95 - $25.56 $211,253 - $300,815	11,769 Added 37.79%	42,913 $782,000
Q1 2021 May 13, 2021	BUY	$20.53 - $25.22 $639,386 - $785,451	31,144 New	31,144 $704,000
Q4 2019 Feb 12, 2020	SELL	$15.15 - $18.89 $413,595 - $515,697	-27,300 Closed	0 $0
Q3 2019 Nov 13, 2019	BUY	$17.68 - $22.65 $482,664 - $618,345	27,300 New	27,300 $483,000
Q1 2019 May 08, 2019	SELL	$19.6 - $24.76 $1.2 Million - $1.51 Million	-61,025 Closed	0 $0
Q4 2018 Feb 12, 2019	BUY	$13.65 - $21.8 $832,991 - $1.33 Million	61,025 New	61,025 $1.2 Million

Others Institutions Holding EXEL

# of Institutions

500

Shares Held

244M

Call Options Held

2.54M

Put Options Held

2.29M

View Full List

About EXELIXIS, INC.

Ticker EXEL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 321,832,000
Market Cap $11.2B
Description
Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ ...

More about EXEL

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Connor, Clark & Lunn Investment Management Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Connor, Clark & Lunn Investment Management Ltd. with notifications on news.

Account

Connor, Clark & Lunn Investment Management Ltd. Exelixis, Inc. Transaction History